Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

4
Cue Biopharma Adds Frank Morich, M.D., Ph.D. to Board of Directors

2018-08-03 globenewswire
CAMBRIDGE, Mass., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today the addition of Frank Morich, M.D., Ph.D., to the Company’s Board of Directors. Dr. Morich is a pharmaceutical executive with over 35 years of leadership experience in immunology, R&D, commercialization and operations who has helped guide both large pharmaceutical and emerging biotechnology companies.
IPHYF IPH INNTY CUE

0
INNATE PHARMA PARTICIPERA A LA 2018 EUROPEAN HEALTHCARE CONFERENCE DE CITI LE 20 JUIN 2018

2018-06-18 globenewswire
Innate Pharma SA (la « Société » - Euronext Paris : FR0010331421 - IPH) annonce aujourd'hui qu'elle sera présente à la Conférence santé européenne 2018 de Citi le 20 juin 2018 à Londres.
IPHYF IPH INNTY

0
Innate Pharma to participate in the Citi 2018 European Healthcare Conference on June 20, 2018

2018-06-18 globenewswire
Innate Pharma (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces that it will be present at the Citi 2018 European Healthcare Conference on June 20, 2018, in London.
IPHYF IPH INNTY

0
Innate pharma à la 3ème journée Oncologie de Bryan Garnier le 13 juin 2018

2018-06-11 globenewswire
Innate Pharma SA (la « Société » - Euronext Paris : FR0010331421 - IPH) annonce aujourd'hui qu'elle sera présente à la 3ème journée Oncologie de Bryan Garnier le 13 juin 2018 à Paris.
IPHYF IPH INNTY

0
Innate Pharma to present at the Bryan Garnier 3rd Annual Oncology Day on June 13, 2018

2018-06-11 globenewswire
Innate Pharma to present at the Bryan Garnier 3rd Annual Oncology Day on June 13, 2018
IPHYF IPH INNTY

0
INNATE PHARMA : Data from Phase I of monalizumab and durvalumab in MSS-CRC at ASCO 2018

2018-06-04 globenewswire
CLINICAL DATA FROM ONGOING PHASE I DOSE ESCALATION AND EXPANSION STUDY OF MONALIZUMAB AND IMFINZI® (DURVALUMAB) IN COLORECTAL cancer PATIENTS PRESENTED AT 2018 ASCO annual meeting
IPHYF IPH INNTY

0
INNATE PHARMA : Outcome of Annual General Meeting of May 29, 2018

2018-05-30 globenewswire
Innate Pharma (Euronext Paris: FR0010331421 - IPH) announces the results of the voting by shareholders at the Annual General Meeting ("AGM") which took place on May 29, 2018, in Marseille, France. Except resolution 33, relating to double voting rights, all resolutions were adopted.
IPHYF IPH INNTY

0
INNATE PHARMA : Résultats de l'Assemblée Générale mixte du 29 mai 2018

2018-05-30 globenewswire
Innate Pharma SA (Euronext Paris : FR0010331421 - IPH) annonce les résultats du vote des actionnaires à l'Assemblée générale mixte qui s'est tenue à Marseille le 29 mai 2018. A l'exception de la résolution 33, relative aux droits de votes doubles, toutes les résolutions ont été adoptées.
IPHYF IPH INNTY

0
INNATE PHARMA : Données préliminaires d'activité de la combinaison monalizumab et durvalumab dans le cancer colorectal

2018-05-17 globenewswire
DES DONNÉES PRÉLIMINAIRES D'UN ESSAI DE PHASE I ÉVALUANT MONALIZUMAB ET IMFINZI® (DURVALUMAB) MONTRENT UNE ACTIVITÉ ANTI-TUMORALE CHEZ DES PATIENTS PRÉSENTANT UN CANCER COLORECTAL
IPHYF IPH INNTY

0
INNATE PHARMA : Preliminary activity observed of the combination of monalizumab and durvalumab in patients with colorectal cancer

2018-05-17 globenewswire
preliminary DATA from a phase I dose escalation and expansion study of monalizumab and Imfinzi® (durvalumab) SHOW ANTI-TUMOR activity in COLORECTAL CANCER patients
IPHYF IPH INNTY

0
INNATE PHARMA : First quarter 2018 report

2018-05-16 globenewswire
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced its revenues and cash position for the first three months of 2018.
IPHYF IPH INNTY

0
INNATE PHARMA : Information financière du premier trimestre 2018

2018-05-16 globenewswire
Innate Pharma SA (La « Société » - Euronext Paris : FR0010331421 - IPH) annonce aujourd'hui son chiffre d'affaires et sa trésorerie pour les trois premiers mois de l'année 2018.
IPHYF IPH INNTY

9
Reader Inquiry: Is InflaRx A Buy On The Dip?

2018-05-13 seekingalpha
At one point shares nearly tripled from their IPO price and have risen by over 60% year to date.
CCXI AAV IPHYF IPH INNTY

0
Innate Pharma annonce la tenue de son AG annuelle le 29 mai 2018 et la mise à disposition de son DDR 2017

2018-04-30 globenewswire
INNATE PHARMA ANNONCE LA TENUE DE SON ASSEMBLEE GENERALE ANNUELLE LE 29 MAI 2018 A MARSEILLE ET LA MISE A DISPOSITION DE SON DOCUMENT DE REFERENCE 2017
IPHYF IPH INNTY

Related Articles

RNVA: Rennova Health Analysis and Research Report

2018-08-18 - Asif

Business overview Rennova Health, Inc. (together with its subsidiaries, “Rennova”, “we” or the “Company”) is a provider of an expanding group of health care services for healthcare providers, patients and individuals. Beginning in 2018, the Company intends to focus on and operate two synergistic divisions: 1) Clinical diagnostics through its clinical laboratories; and 2) Hospital operations through its Big South Fork Medical Center, which opened on August 8, 2017, and a hospital in Jamestown Tennessee, including a doctor’s practice, the assets of which the company expect to acquire in the second quarter of 2018, pursuant to the terms of a definitive asset purchase agreement that the company entered into on January 31, 2018, as more fully discussed below. The company believe that its approach will produce a more sustainable business model and the capture of multiple revenue streams from medical providers, patients and hospital services. Management determined that because Big So...

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...